StreetInsider.com News Articles

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

Wed, 21 Oct 2026 08:00:00 -0400

Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups

PETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present an oral presentation at IDWeek 2026 on Thursday, October 22, 2026, in Washington, D.C. The presentation will focus on an exploratory pooled analysis of microbiology from SHIELD I, SHIELD II, and D-PLEX₁₀₀ phase 2 trial involving 2,185 patients, demonstrating a

PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026

Wed, 21 Oct 2026 08:00:00 -0400

Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

Thu, 15 Oct 2026 08:30:00 -0400

Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy

Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases

Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it will host a virtual Investor Day on Wednesday, October 28, 2026, at 11:30 a.m. ET.

During the event, PolyPid’s management team will outline the Company’s “PolyPid 2030” long-term growth and

PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

Thu, 15 Oct 2026 08:30:00 -0400

Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy

Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases

During the event, PolyPid’s management team will outline the Company’s “PolyPid 2030” long-term growth and

Form 6-K PolyPid Ltd. For: Oct 01

Thu, 01 Oct 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20261001/27132897.html

EMA validates PolyPid's marketing application for D-PLEX100

Thu, 01 Oct 2026 09:15:17 -0400

PolyPid Ltd. (NASDAQ: PYPD) announced that the European Medicines Agency has validated the company's Marketing Authorization Application for D-PLEX100, a drug candidate intended to prevent incisional infections following abdominal surgery.

The MAA was submitted to the EMA on September 14, 2026, under the Centralized Procedure on the basis of therapeutic innovation. Validation confirms the application is complete and triggers formal review by the EMA's Committee for Medicinal Products for Human Use. If approved, D-PLEX100 would receive a single marketing authorization valid across all European Union member states.

The application is supported by data from the Phase 3 SHIELD II trial, which the

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

Thu, 01 Oct 2026 09:15:00 -0400

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month

Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀

D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that the European Medicines Agency (“EMA”) has validated the Company’s recently submitted Marketing Authorization Application (“MAA”) for D-PLEX₁₀₀,

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

Thu, 01 Oct 2026 09:15:00 -0400

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month

Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀

D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date

Form 6-K PolyPid Ltd. For: Oct 01

Thu, 01 Oct 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20261001/27132667.html

PolyPid regains European rights to D-PLEX100 after ADVANZ deal ends

Thu, 01 Oct 2026 08:56:39 -0400

PolyPid Ltd. (NASDAQ: PYPD) and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe, according to a company statement. As a result, the European commercialization rights for the drug have reverted to PolyPid.

The original agreement was signed in 2022. Since then, PolyPid said it completed its Phase 3 SHIELD II trial, submitted a New Drug Application to the U.S. Food and Drug Administration, filed with the European Medicines Agency, and entered into a North American commercialization partnership with Azurity Pharmaceuticals.

"We appreciate the collaboration with the ADVANZ PHARMA team over the

PolyPid regains European rights to D-PLEX100 after ADVANZ deal ends

Thu, 01 Oct 2026 08:56:39 -0400

"We appreciate the collaboration with the ADVANZ PHARMA team over the

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

Thu, 01 Oct 2026 08:56:00 -0400

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid.

"We appreciate the collaboration with the ADVANZ PHARMA team over the past several years and thank them for working with us to reach a

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

Thu, 01 Oct 2026 08:56:00 -0400

"We appreciate the collaboration with the ADVANZ PHARMA team over the past several years and thank them for working with us to reach a

PolyPid Announces Participation in Upcoming Fall Investor Conferences

Tue, 15 Sep 2026 08:30:00 -0400

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:

5th Annual ROTH Healthcare Opportunities Conference
Dates: September 29, 2026
Location: Metropolitan Club, New York, NY
Format: Panel discussion and one-on-one investor meetings
Panel: “The Biotech Reset: Regulatory Uncertainty, Capital Constraints and the Search for Value,” 12:00-12:30 p.m. ET

Investors interested in meeting with PolyPid should contact their ROTH

PolyPid Announces Participation in Upcoming Fall Investor Conferences

Tue, 15 Sep 2026 08:30:00 -0400

Investors interested in meeting with PolyPid should contact their ROTH

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Centaurus Investments Ltd

Thu, 13 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26921710.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Centaurus Investments Ltd

Thu, 13 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26921710.html

Form 6-K PolyPid Ltd. For: Jun 30

Wed, 12 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260812/26913968.html

Form 6-K PolyPid Ltd. For: Jun 30

Wed, 12 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260812/26913968.html

Form S-8 PolyPid Ltd.

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912592.html

Form S-8 PolyPid Ltd.

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912592.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911871.html

Form SCHEDULE 13G/A PolyPid Ltd. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260812/26911871.html

PolyPid Ltd. (PYPD) Tops Q2 EPS by 5c

Wed, 12 Aug 2026 07:47:27 -0400

PolyPid Ltd. (NASDAQ: PYPD) reported Q2 EPS of ($0.35), $0.05 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on PolyPid Ltd. (PYPD) click here.

Form 6-K PolyPid Ltd. For: Aug 12

Wed, 12 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260812/26908972.html